BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hydroxychloroquine readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Hydroxychloroquine\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05843188-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Hydroxychloroquine: Phase 2 readout est. (NCT05843188)
DESCRIPTION:Hydroxychloroquine\, phase 2.\nStudy: Study of Hydroxychloroqui
 ne With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer\n
 Estimated primary completion: 24 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05843188
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06467526-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Hydroxychloroquine: Phase 2 readout est. (NCT06467526)
DESCRIPTION:Hydroxychloroquine\, phase 2.\nStudy: Efficacy and Safety of Hy
 droxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss\nEs
 timated primary completion: 31 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/hydroxychloroquine#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06467526
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06519617-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Hydroxychloroquine: Phase 2 readout est. (NCT06519617)
DESCRIPTION:Hydroxychloroquine\, phase 2.\nStudy: Study on Optimization and
  Evaluation of Integrated Chinese and Western Medicine for pSS Glandular D
 amage\nEstimated primary completion: 31 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06519617
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05041907-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Hydroxychloroquine: Phase 2 readout est. (NCT05041907)
DESCRIPTION:Hydroxychloroquine\, phase 2.\nStudy: Finding Treatments for CO
 VID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-1
 9 (PLATCOV)\nEstimated primary completion: January 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05041907
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05036226-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270521
DTEND;VALUE=DATE:20270522
SUMMARY:Hydroxychloroquine: Phase 1/2 readout est. (NCT05036226)
DESCRIPTION:Hydroxychloroquine\, phase 1/2.\nStudy: COAST Therapy in Advanc
 ed Solid Tumors and Prostate Cancer\nEstimated primary completion: 21 May 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/hydroxychloroqu
 ine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05036226
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03598595-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Hydroxychloroquine: Phase 1/2 readout est. (NCT03598595)
DESCRIPTION:Hydroxychloroquine\, phase 1/2.\nStudy: Gemcitabine\, Docetaxel
 \, and Hydroxychloroquine in Treating Participants With Recurrent or Refra
 ctory Osteosarcoma\nEstimated primary completion: 31 May 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/hydroxychloroquine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03598595
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04911816-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Hydroxychloroquine: Phase 1/2 readout est. (NCT04911816)
DESCRIPTION:Hydroxychloroquine\, phase 1/2.\nStudy: Neoadjuvant mFOLFIRINOX
  With Perioperative Oral Hydroxychloroquine in Resectable Pancreatic Adeno
 carcinoma\nEstimated primary completion: June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04911816
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04841148-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Hydroxychloroquine: Phase 2 readout est. (NCT04841148)
DESCRIPTION:Hydroxychloroquine\, phase 2.\nStudy: Avelumab or Hydroxychloro
 quine With or Without Palbociclib to Eliminate Dormant Breast Cancer\nEsti
 mated primary completion: July 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/hydroxychloroquine#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04841148
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06816810-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Hydroxychloroquine: Phase 2 readout est. (NCT06816810)
DESCRIPTION:Hydroxychloroquine\, phase 2.\nStudy: A Study to Evaluate Effic
 acy\, Safety and Tolerability of Hydroxychloroquine in Subjects With Parki
 nson's Disease\nEstimated primary completion: September 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/hydroxychloroquine#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06816810
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07443436-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Hydroxychloroquine: Phase 2 readout est. (NCT07443436)
DESCRIPTION:Hydroxychloroquine\, phase 2.\nStudy: Immunomodulatory Treatmen
 t of Interstitial Lung Disease Associated With Surfactant Related Gene Var
 iants\nEstimated primary completion: 1 November 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07443436
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04523857-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Hydroxychloroquine: Phase 2 readout est. (NCT04523857)
DESCRIPTION:Hydroxychloroquine\, phase 2.\nStudy: ABemacicliB or Abemacicli
 b and HydroxYchloroquine to Target Minimal Residual Disease in Breast Canc
 er\nEstimated primary completion: December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT04523857
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07467252-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Hydroxychloroquine: Phase 2 readout est. (NCT07467252)
DESCRIPTION:Hydroxychloroquine\, phase 2.\nStudy: AIPH-TB: AI-Optimised Pyr
 azinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary
  Tuberculosis - A Phase II RCT\nEstimated primary completion: December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/hydroxychloroquine
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074
 67252
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06350630-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Hydroxychloroquine: Phase 2 readout est. (NCT06350630)
DESCRIPTION:Hydroxychloroquine\, phase 2.\nStudy: Therapeutic Effect of Hyd
 roxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study\
 nEstimated primary completion: 31 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06350630
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05287321-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Hydroxychloroquine: Phase 3 readout est. (NCT05287321)
DESCRIPTION:Hydroxychloroquine\, phase 3.\nStudy: The Efficacy of Aspirin C
 ombined With Hydroxychloroquine Treatment in High Risk Pregnancies for Pre
 eclampsia\nEstimated primary completion: 31 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05287321
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07138898-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Hydroxychloroquine: Phase 2 readout est. (NCT07138898)
DESCRIPTION:Hydroxychloroquine\, phase 2.\nStudy: Immunosuppressant Managem
 ent in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplas
 ty\nEstimated primary completion: January 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07138898
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05733000-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280104
DTEND;VALUE=DATE:20280105
SUMMARY:Hydroxychloroquine: Phase 2 readout est. (NCT05733000)
DESCRIPTION:Hydroxychloroquine\, phase 2.\nStudy: CPI-613 (Devimistat) in C
 ombination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Tr
 eating Patients With Advanced Chemorefractory Solid Tumors\nEstimated prim
 ary completion: 4 January 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/hydroxychloroquine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05733000
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Hydroxychloroquine: Phase 3 readout est. (NCT03414502)
DESCRIPTION:Hydroxychloroquine\, phase 3\, Rheumatoid Arthritis.\nStudy: Tr
 eatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEstim
 ated primary completion: March 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/hydroxychloroquine#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07814339-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Hydroxychloroquine: Phase 1 readout est. (NCT07814339)
DESCRIPTION:Hydroxychloroquine\, phase 1.\nStudy: Hydrochloroquinine & Deci
 tabine With Venetoclax in AML\nEstimated primary completion: June 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/hydroxychloroquine#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07814339
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02735707-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Hydroxychloroquine: Phase 3 readout est. (NCT02735707)
DESCRIPTION:Hydroxychloroquine\, phase 3.\nStudy: Randomized\, Embedded\, M
 ultifactorial Adaptive Platform Trial for Community- Acquired Pneumonia\nE
 stimated primary completion: June 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/hydroxychloroquine#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT02735707
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06971744-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280618
DTEND;VALUE=DATE:20280619
SUMMARY:Hydroxychloroquine: Phase 2 readout est. (NCT06971744)
DESCRIPTION:Hydroxychloroquine\, phase 2.\nStudy: Autophagy Maintenance (AU
 TOMAIN)\nEstimated primary completion: 18 June 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06971744
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04354649-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Hydroxychloroquine: Phase 2 readout est. (NCT04354649)
DESCRIPTION:Hydroxychloroquine\, phase 2.\nStudy: Immune-Mediated Pathophys
 iology And Clinical Triage Program\nEstimated primary completion: July 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/hydroxychloroquine
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT043
 54649
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04381936-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Hydroxychloroquine: Phase 3 readout est. (NCT04381936)
DESCRIPTION:Hydroxychloroquine\, phase 3.\nStudy: Randomised Evaluation of 
 COVID-19 Therapy\nEstimated primary completion: 30 September 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/hydroxychloroquine#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04381936
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05799378-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Hydroxychloroquine: Phase 3 readout est. (NCT05799378)
DESCRIPTION:Hydroxychloroquine\, phase 3\, Systemic Lupus Erythematosus.\nS
 tudy: Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease\nEst
 imated primary completion: 31 December 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/hydroxychloroquine#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05799378
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07675291-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Hydroxychloroquine: Phase na readout est. (NCT07675291)
DESCRIPTION:Hydroxychloroquine\, phase na\, Systemic Lupus Erythematosus.\n
 Study: Rituximab Combining With Low-Dose Mycophenolate Mofetil on Prolifer
 ative Lupus Nephritis in Children\nEstimated primary completion: 31 Decemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/hydroxychlor
 oquine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07675291
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06408298-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Hydroxychloroquine: Phase 1 readout est. (NCT06408298)
DESCRIPTION:Hydroxychloroquine\, phase 1.\nStudy: HCQ in Resectable Localiz
 ed Prostate Cancer\nEstimated primary completion: February 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/hydroxychloroquine#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06408298
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07061717-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Hydroxychloroquine: Phase 3 readout est. (NCT07061717)
DESCRIPTION:Hydroxychloroquine\, phase 3.\nStudy: Comparing Endocrine Thera
 py Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine
  Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Posi
 tive and HER2-Negative Advanced Breast Cancer\nEstimated primary completio
 n: 1 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hydro
 xychloroquine#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07061717
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05841758-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Hydroxychloroquine: Phase 4 readout est. (NCT05841758)
DESCRIPTION:Hydroxychloroquine\, phase 4.\nStudy: Hydroxychloroquine as a S
 teroid-sparing Agent in Extrapulmonary Sarcoidosis\nEstimated primary comp
 letion: 1 July 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 hydroxychloroquine#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05841758
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06676384-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Hydroxychloroquine: Phase 4 readout est. (NCT06676384)
DESCRIPTION:Hydroxychloroquine\, phase 4.\nStudy: Which of the Commonly Ava
 ilable and Approved Drugs in Addition to Standard of Care Can Significantl
 y Improve the Slope of Estimated Glomerular Filtration Rate at Two Years W
 hen Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven
  Adult (≥18 Years) Primary IgA Nephropathy?\nEstimated primary completio
 n: August 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hydro
 xychloroquine#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06676384
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05842174-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Hydroxychloroquine: Phase 1/2 readout est. (NCT05842174)
DESCRIPTION:Hydroxychloroquine\, phase 1/2.\nStudy: Targeting Ischemia-Indu
 ced Autophagy Dependence in Hepatocellular Carcinoma\nEstimated primary co
 mpletion: 30 September 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/hydroxychloroquine#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05842174
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07825454-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Hydroxychloroquine: Phase 2 readout est. (NCT07825454)
DESCRIPTION:Hydroxychloroquine\, phase 2.\nStudy: Pilot Study of Hydroxychl
 oroquine for the Treatment of AIMSS\nEstimated primary completion: Decembe
 r 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/hydroxychloro
 quine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07825454
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352566-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Hydroxychloroquine: Phase 4 readout est. (NCT07352566)
DESCRIPTION:Hydroxychloroquine\, phase 4.\nStudy: Utilization of a Microdev
 ice for Psoriasis and Atopic Dermatitis\nEstimated primary completion: 1 J
 une 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hydroxychlo
 roquine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07352566
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07750067-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20300728
DTEND;VALUE=DATE:20300729
SUMMARY:Hydroxychloroquine: Phase 2 readout est. (NCT07750067)
DESCRIPTION:Hydroxychloroquine\, phase 2.\nStudy: Tunlametinib in Combinati
 on With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma\nEstim
 ated primary completion: 28 July 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/hydroxychloroquine#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07750067
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07265297-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Hydroxychloroquine: Phase 3 readout est. (NCT07265297)
DESCRIPTION:Hydroxychloroquine\, phase 3.\nStudy: Using Hydroxychloroquine 
 (HCQ) to Treat Steatohepatitis\nEstimated primary completion: 31 December 
 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/hydroxychloroqu
 ine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07265297
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07830108-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20341231
DTEND;VALUE=DATE:20350101
SUMMARY:Hydroxychloroquine: Phase 3 readout est. (NCT07830108)
DESCRIPTION:Hydroxychloroquine\, phase 3.\nStudy: ACT4RHD is an Open-label\
 , Randomised\, Adaptive Platform Trial to Evaluate Novel and Repurposed Cl
 inical Interventions for Patients With Acute Rheumatic Fever and Carditis.
  ACT4RHD Seeks to Determine Whether These Interventions Reduce RHD Severit
 y at 6 Months.\nEstimated primary completion: December 2034. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07830108
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06652113-5478@assetmemo.bio
DTSTAMP:20261121T004014Z
DTSTART;VALUE=DATE:20350331
DTEND;VALUE=DATE:20350401
SUMMARY:Hydroxychloroquine: Phase na readout est. (NCT06652113)
DESCRIPTION:Hydroxychloroquine\, phase na.\nStudy: Effect of HCQ Combined W
 ith LT4 on LBR in Euthyroid Women With URPL and TPO-Ab\nEstimated primary 
 completion: March 2035. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/hydroxychloroquine#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06652113
URL:https://assetmemo.bio/drug/hydroxychloroquine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
